title: [Effect of ulinastatin on the management of early myocardiac injury after severe burns].
abstract: OBJECTIVE
  To investigate the effect of Ulinastatin on the management of early myocardial injury and its mechanisms.
  
  
  METHODS
  Thirty-four severe burn patients with TBSA exceeding 50% were admitted into our hospital within 24 hrs after burns, and they were divided into burn group (n=17) and ulinastatin-treated group (n=17, UTI group). All patients received conventional treatment. The patients in UTI group were given 100,000 U ulinastatin intravenously immediately after admission, 3 times a day for a week. The plasma content of troponin I (cTnI) , creatine kinase (CK-MB) and PMN elastase were determined on 2, 4 and 7 postburn days (PBD), and the correlate relationship among these three indices were analyzed.
  
  
  RESULTS
  (1) The plasma content of cTnI and PMN elastase at 2, 4, 7 PBDs were significantly higher than that of normal value (P < 0.01), but they were obviously lower in UTI group than that in burn group. (2) Compared with normal value, the plasma content of CK-MB in burn group was increased significantly on 2, 4 and 7 PBDs (P < 0.01), and it reached the peak on 4 PBD. Though it was obviously higher in UTS group on 2 and 4 PBDs compared with the normal value, but it was lower than that in burn group ( P < 0.05 or 0.01) , and it returned to normal value on 7 PBD. (3) There exhibited positive correlation among the PMN elastase content, cTnI content and CK-MB activity of the 34 patients. The correlation index of PMN elastase content and cTnI content was 0. 904, while that between cTnI content and CK-MB activity was 0.922, and that between PMN elastase content and CK-MB activity was 0.829 (P < 0.01).
  
  
  CONCLUSIONS
  Ulinastatin is beneficial in alleviating myocardial injury after severe burns, and it reduces the release of PMN elastase.
authors.affiliation: Institute of Burn Research, Southwest Hospital, State Key Laboratory of Trauma, Burns and Combined Injury, The Third Military Medical University, Chongqing 400038, PR China.
authors.forename: Kang
authors.initials: K
authors.lastname: Xie
authors.forename: Yue-sheng
authors.initials: YS
authors.lastname: Huang
authors.forename: Rui
authors.initials: R
authors.lastname: An
authors.forename: Jun-li
authors.initials: JL
authors.lastname: Zhou
authors.forename: Jia-ping
authors.initials: JP
authors.lastname: Zhang
mesh_terms: D000328:Adult; D002056:Burns / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D006801:Humans; D019272:Leukocyte Elastase / Q000097:blood; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D020107:Troponin T / Q000097:blood
chemical_list: D006023:Glycoproteins; D020107:Troponin T; D003402:Creatine Kinase; D019272:Leukocyte Elastase; C028665:urinastatin